Skip to main content
Clinical Trials/NCT03539783
NCT03539783
Completed
Not Applicable

Identification of Pediatric Acute Respiratory Distress Syndrome Subtypes by Bronchial and Nasal Epithelial Transcriptomics

Children's Hospital Medical Center, Cincinnati2 sites in 1 country76 target enrollmentApril 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Respiratory Distress Syndrome
Sponsor
Children's Hospital Medical Center, Cincinnati
Enrollment
76
Locations
2
Primary Endpoint
Identification of PARDS Endotypes
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Pediatric acute respiratory distress syndrome (PARDS) is a severe and diffuse lung injury that is a common cause of admission and mortality in the pediatric intensive care unit (PICU). PARDS can be secondary to many different causes, and there are few therapies that have been shown beneficial in PARDS. This study seeks to identify important PARDS subtypes using gene expression profiling of bronchial epithelial cells from control and PARDS subjects.

Detailed Description

Enrolled subjects will have nasal brushings collected at days 1, 3, 7, and 14 of intubation with collection of serum at these same time points. Brushing RNA will be processed by mRNA-Seq for gene expression analysis and compared to previously published serum biomarkers (interleukin-8, advanced glycosylation end-product specific receptor, and angiopoietin-2) to assess correlation and ability to discriminate PARDS endotypes. Changes in gene expression over time will be assessed to define a PARDS recovery gene expression signature, and correlation between bronchial and nasal gene expression will be determined.

Registry
clinicaltrials.gov
Start Date
April 1, 2018
End Date
September 5, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All potential participants must:
  • Be aged zero to 18 years (both control and ARDS, not age matched)
  • Be admitted to the PICU with expected duration of hospitalization 7 days or greater.
  • ARDS patients must:
  • Have acute changes in chest x-ray (CXR)
  • Have a known or suspected insult within the prior 7 days that is consistent with ARDS
  • Have an oxygenation index (OI) of 4 or greater or and oxygen-sat index (OSI) of 5 or greater
  • OI = mean airway pressure X fraction inspired oxygen (FiO2) / arterial oxygen partial pressure (PaO2)
  • OSI = mean airway pressure X FiO2 / oxyhemoglobin saturation (SpO2) with sat \<= 97%.

Exclusion Criteria

  • Have a baseline oxygen requirement of 2 liters of oxygen or greater at home
  • Have disruption of the nasal passages
  • Have a history of excessive bleeding or known bleeding disorders
  • Be at high risk of bleeding
  • Have a do not resuscitate (DNR) or Limited Resuscitation Order

Outcomes

Primary Outcomes

Identification of PARDS Endotypes

Time Frame: 6 years

Use of unbiased cluster analysis of gene expression to identify subtypes in PARDS

Secondary Outcomes

  • Correlation of Nasal and Bronchial Gene Expression(6 years)
  • Lung Recovery Gene Expression Profile(6 years)
  • Correlation of Endotypes with Lung Cell-specific Biomarkers(6 years)

Study Sites (2)

Loading locations...

Similar Trials